Drug Profile

AMY 109

Alternative Names: AMY-109

Latest Information Update: 29 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Chugai Pharmaceutical
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Interleukin 8 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Endometriosis; Solid tumours

Most Recent Events

30 Jun 2025 Discontinued - Phase-I for Solid tumours (Second-line therapy or greater, Combination therapy, Late-stage disease) in Japan (Parenteral) (Chugai Pharmaceuticals pipeline, August 2025)
30 Jun 2025 Discontinued - Phase-II for Endometriosis in Japan, World (SC) (Chugai Pharmaceuticals pipeline, August 2025)
31 Jan 2024 Phase-II clinical trials in Endometriosis in World (SC) (Chugai pharmaceutical pipeline, February 2024)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com